Author Archives: Administrator

RJX Community

RJX Community Reven, never backward, patient forward. — Com·mu·ni·ty (noun): a feeling of fellowship with others. Similar: body, society, collective — Reven has a dedicated mission to serve patients and their loved ones. Amidst these trying times, our collaborations with … Read More

2020/03/28 Reven News Press

A Phase 1, Double-blind, Placebo-controlled, Randomized, Two-Part, Ascending Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Rejuveinix (RJX) in Healthy Participants. Click here for the full study details

2020/03/23 Reven News Press

Reven successfully completes Phase I clinical trials and is pleased to announce completion with no Serious Adverse Events and no Unexpected Adverse Events.  Results are expected to be submitted to the FDA during the next few weeks.

2020/03/22 Reven News Press

Reven announces Phase II Clinical Development plans for upcoming human efficacy trials.  These trials include exploring efficacy as an adjunct therapy for patients suffering Critical Limb Ischemia.  Additional areas of focus in separate trials will be for chronic wound healing … Read More

2020/03/21 Reven News Press

Reven will soon kick off a social media campaign to get the word out about the exciting developments relative to RJX moving through the regulatory pathway. Please seek us out on Facebook, Instagram, Twitter, LinkedIn and like/comment on our posts … Read More

07/10/2017 Reven News Press

Reven selected an Australian Contract Manufacturing Organization (CMO) to supply drug product for Phase I Clinical Trial

07/03/2017 Reven News Press

Canadian Intellectual Property Office approved our Family Two patent in Canada

06/12/2017 Reven News Press

The US Patent and Trademark Office (USPTO) allowed Reven RJX Family One Child Patent, application # 14,550,677. This is our “method of treating” patent.

06/12/2017 Reven News Press 2

Reven selected Linear Clinical Research as the Phase I research site in Australia.

06/05/2017 Reven News Press

Reven initiates Phase I Clinical Trial in Australia to run in conjunction with planned Phase I/IIa in the USA

03/01/2017 Reven News Press

Drs. Michael Davies, Philip Barter, and Jonathan Golledge join Medical Advisory Board.